These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 21929482)

  • 1. Safety of incretin-based therapies for type 2 diabetes.
    Davis TM
    Med J Aust; 2011 Sep; 195(6):312-3. PubMed ID: 21929482
    [No Abstract]   [Full Text] [Related]  

  • 2. Incretin-based therapies: facing the realities of benefits versus side effects.
    Lebovitz HE
    Diabetes Technol Ther; 2013 Nov; 15(11):909-13. PubMed ID: 24111860
    [No Abstract]   [Full Text] [Related]  

  • 3. Novo Nordisk incretin and Cardiovascular Summit, Durban, June 2013.
    Wagenaar P
    Cardiovasc J Afr; 2013 Sep; 24(8):340. PubMed ID: 24240386
    [No Abstract]   [Full Text] [Related]  

  • 4. The role of incretin-based therapies in the management of type 2 diabetes.
    Bandyopadhyay P
    Drug News Perspect; 2009 Nov; 22(9):559-67. PubMed ID: 20072733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insulin degludec/liraglutide (Xultophy 100/3.6) for type 2 diabetes.
    Med Lett Drugs Ther; 2017 Sep; 59(1529):147-149. PubMed ID: 28880845
    [No Abstract]   [Full Text] [Related]  

  • 6. Incretin-based therapies for type 2 diabetes mellitus: current status and future prospects.
    Drab SR
    Pharmacotherapy; 2010 Jun; 30(6):609-24. PubMed ID: 20500049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incretin-based therapies for type 2 diabetes mellitus: New therapeutic mechanisms.
    Kennedy L
    Cleve Clin J Med; 2009 Dec; 76 Suppl 5():S2-3. PubMed ID: 19952299
    [No Abstract]   [Full Text] [Related]  

  • 8. Glucagon-like peptide-1 receptor agonists: the key to healthy weight loss maintenance?
    Lehmann EW; Torekov SS
    Cardiovasc Res; 2021 Aug; 117(10):e120-e122. PubMed ID: 34448813
    [No Abstract]   [Full Text] [Related]  

  • 9. Incretin therapy and its effect on body weight in patients with diabetes.
    Lind M
    Prim Care Diabetes; 2012 Oct; 6(3):187-91. PubMed ID: 22613745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Incretin-based therapy in type 2 diabetes does not increase the risk of hospitalization for heart failure].
    Steurer J
    Praxis (Bern 1994); 2016 Jun; 105(13):785-6. PubMed ID: 27329712
    [No Abstract]   [Full Text] [Related]  

  • 11. Differentiating among incretin therapies: a multiple-target approach to type 2 diabetes.
    Cornell S
    J Clin Pharm Ther; 2012 Oct; 37(5):510-24. PubMed ID: 22436069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incretin-based therapy for type 2 diabetes: A real class effect?
    Savarese G; Lund LH; Rosano GMC
    Int J Cardiol; 2017 Jan; 227():141-142. PubMed ID: 27866064
    [No Abstract]   [Full Text] [Related]  

  • 13. Incretins: cardiovascular safety and rationale for use.
    Kok A
    Cardiovasc J Afr; 2013 Mar; 24(2):46. PubMed ID: 23750348
    [No Abstract]   [Full Text] [Related]  

  • 14. Cardiovascular safety of combination therapies with incretin-based drugs and metformin compared with a combination of metformin and sulphonylurea in type 2 diabetes mellitus--a retrospective nationwide study.
    Mogensen UM; Andersson C; Fosbøl EL; Schramm TK; Vaag A; Scheller NM; Torp-Pedersen C; Gislason G; Køber L
    Diabetes Obes Metab; 2014 Oct; 16(10):1001-8. PubMed ID: 24827939
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and economic implications of incretin-based therapies.
    Briggs GC
    Endocrinol Metab Clin North Am; 2007 Dec; 36 Suppl 2 Incretin():18-26. PubMed ID: 18405145
    [No Abstract]   [Full Text] [Related]  

  • 16. Incretin-based therapy in type 2 diabetes: An evidence based systematic review and meta-analysis.
    Waldrop G; Zhong J; Peters M; Goud A; Chen YH; Davis SN; Mukherjee B; Rajagopalan S
    J Diabetes Complications; 2018 Jan; 32(1):113-122. PubMed ID: 29074120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The safety of incretin based drugs.
    Montori VM
    BMJ; 2014 Apr; 348():g2779. PubMed ID: 24764568
    [No Abstract]   [Full Text] [Related]  

  • 18. Albiglutide: a new GLP-1 analog for the treatment of type 2 diabetes.
    St Onge EL; Miller SA
    Expert Opin Biol Ther; 2010 May; 10(5):801-6. PubMed ID: 20367248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incretin-based therapies are associated with acute pancreatitis: Meta-analysis of large randomized controlled trials.
    Roshanov PS; Dennis BB
    Diabetes Res Clin Pract; 2015 Dec; 110(3):e13-7. PubMed ID: 26643128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Q: Do incretin drugs for type 2 diabetes increase the risk of acute pancreatitis?
    Olansky L
    Cleve Clin J Med; 2010 Aug; 77(8):503-5. PubMed ID: 20682512
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.